Henry Schein (HSIC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 net sales were $3.471B, up 4.0% reported; internal growth was 3.1%.
Adjusted non-GAAP diluted EPS, excluding Q3 tariff refunds and prior-year remeasurement gains, rose 19.1% to $1.37.
FY2026 non-GAAP EPS guidance increased to $5.50–$5.56; sales growth guidance remained 4.5%–5.5%.
Financial highlights
GAAP net income was $119M versus $101M; diluted EPS was $1.06 versus $0.84.
Non-GAAP net income was $175M versus $167M; diluted EPS was $1.56 versus $1.38, up 13.0%.
Gross profit was $1.105B, up 7.7%; non-GAAP gross margin was 31.83%, up 111 bps.
Non-GAAP operating income rose 6.6% to $279M; operating margin was 8.03%, up 20 bps.
Adjusted EBITDA increased 8.7% to $321M; Q3 operating cash flow was $161M.
Outlook and guidance
FY2026 non-GAAP diluted EPS guidance rose from $5.29–$5.39 to $5.50–$5.56; adjusted EBITDA growth guidance is high-single-digit.
Guidance reflects Q3 tariff-refund benefits, improved underlying performance and targeted, limited Q4 growth investments; no significant further tariff refunds or remeasurement gains are assumed.
Guidance assumes FX rates generally consistent with current levels and an effective non-GAAP tax rate of ~24%.
No GAAP guidance was issued because restructuring and related costs could not be estimated without unreasonable effort.
Latest events from Henry Schein
- FY2025 sales grew 4%, with a 2027 target to source over half of non-GAAP operating income from high-growth businesses.HSIC
Corporate presentation - Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance.HSIC
2026 Global Healthcare Conference - Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Q2 2026 saw strong sales, margin gains, and raised guidance, with robust segment growth.HSIC
Q2 2026 - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 2025 - Transformation, innovation, and disciplined growth drive strong outlook and value creation.HSIC
Stifel Jaws & Paws Conference 2026 - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024